Galactose decorated PLGA nanoparticles for hepatic delivery of acyclovir

References

• Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL et al.; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis B Virus Study Group. (2007). Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol, 5:921–931.
   PubMed Web of Science ®Google Scholar
• Lavanchy D. (2004). Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat, 11:97–107.
   PubMed Web of Science ®Google Scholar
• McMahon BJ, Holck P, Bulkow L, Snowball M. (2001). Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med, 135:759–768.
   PubMed Web of Science ®Google Scholar
• Ganem D, Prince AM. (2004). Hepatitis B virus infection–natural history and clinical consequences. N Engl J Med, 350:1118–1129.
   PubMed Web of Science ®Google Scholar
• Davoodian P, Dadvand H, Mahoori K, Amoozandeh A, Salavati A. (2009). Prevalence of selected sexually and blood-borne infections in Injecting drug abuser inmates of bandar abbas and roodan correction facilities, Iran, 2002. Braz J Infect Dis, 13:356–358.
   PubMed Web of Science ®Google Scholar
• Märker-Hermann E, Schütz N, Bauer H. (2010). [Viral arthritides]. Z Rheumatol, 69:871–878.
   PubMed Web of Science ®Google Scholar
• Zhang YL, Pan HY, Chen CR, Lou GQ, Ye RX, Lu DR. (2008). [The roles of saliva testing for preventing hepatitis B virus spreading]. Zhonghua Yu Fang Yi Xue Za Zhi, 42:596–598.
   PubMedGoogle Scholar
• Sanjay S, Huang P, Lavanya R. (2011). Herpes zoster ophthalmicus. Curr Treat Options Neurol, 13:79–91.
   PubMed Web of Science ®Google Scholar
• Lolis MS, González L, Cohen PJ, Schwartz RA. (2008). Drug-resistant herpes simplex virus in HIV infected patients. Acta Dermatovenerol Croat, 16:204–208.
   PubMed Web of Science ®Google Scholar
• Jones CA, Walker KS, Badawi N. (2009). Antiviral agents for treatment of herpes simplex virus infection in neonates. Cochrane Database Syst Rev, 8:CD004206.
   Google Scholar
• Hostetler KY, Beadle JR, Hornbuckle WE, Bellezza CA, Tochkov IA, Cote PJ et al. (2000). Antiviral activities of oral 1-O-hexadecylpropanediol-3-phosphoacyclovir and acyclovir in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother, 44:1964–1969.
   PubMed Web of Science ®Google Scholar
• Kern ER, Palmer J, Szczech G, Painter G, Hostetler KY. (2000). Efficacy of topical acyclovir monophosphate, acyclovir, or penciclovir in orofacial HSV-1 infections of mice and genital HSV-2 infections of guinea pigs. Nucleosides Nucleotides Nucleic Acids, 19:501–513.
   PubMed Web of Science ®Google Scholar
• Haefeli WE, Schoenenberger RA, Weiss P, Ritz RF. (1993). Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose. Am J Med, 94:212–215.
   PubMed Web of Science ®Google Scholar
• Stulzera HK, Tagliarib MP, ParizeaAL, Silvab MAS, Laranjeiraa MCM. (2008). Evaluation of cross-linked chitosan microparticles containing acyclovir obtained by spray-drying. Mater Sci Eng C, 29:387–392.
   Google Scholar
• Saraogi GK, Gupta P, Gupta UD, Jain NK, Agrawal GP. (2010). Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int J Pharm, 385:143–149.
   PubMed Web of Science ®Google Scholar
• Nahar M, Mishra D, Dubey V, Jain NK. (2008). Development, characterization, and toxicity evaluation of amphotericin B-loaded gelatin nanoparticles. Nanomedicine, 4:252–261.
   PubMed Web of Science ®Google Scholar
• Rolland JP, Maynor BW, Euliss LE, Exner AE, Denison GM, DeSimone JM. (2005). Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J Am Chem Soc, 127:10096–10100.
   PubMed Web of Science ®Google Scholar
• Jain PK, ElSayed IH, El-Sayed MA. (2007). Au nanoparticles target cancer. Nano Today, 2:18–29.
   Web of Science ®Google Scholar
• Li Y, Wei P, Li J, Li L. (2011). Pharmacokinetic analysis and optimization of hydroxycamptothecin-loaded nanoparticles for liver targeting. Drug Dev Ind Pharm, (In Press).
   Web of Science ®Google Scholar
• Andersson LI, Hellman P, Eriksson H. (2008). Receptor-mediated endocytosis of particles by peripheral dendritic cells. Hum Immunol, 69:625–633.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Shiramoto S, Miyashita M, Fujishima Y, Kaneo Y. (2004). Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int J Pharm, 277:39–61.
   PubMed Web of Science ®Google Scholar
• Klose D, Siepmann F, Elkharraz K, Siepmann J. (2008). PLGA-based drug delivery systems: importance of the type of drug and device geometry. Int J Pharm, 354:95–103.
   PubMed Web of Science ®Google Scholar
• Wang Y, Jiang G, Qiu T, Ding F. (2011). Preparation and evaluation of paclitaxel-loaded nanoparticle incorporated with galactose-carrying polymer for hepatocyte targeted delivery. Drug Dev Ind Pharm, doi:10.3109/03639045.2011.637052.
   Web of Science ®Google Scholar
• Okuno K, Nakamura K, Tanaka A, Yachi K, Yasutomi M. (1998). Hepatic immunopotentiation by galactose-entrapped liposomal IL-2 compound in the treatment of liver metastases. Surg Today, 28:64–69.
   PubMed Web of Science ®Google Scholar
• Kohgo Y, Kato J, Nakaya R, Mogi Y, Yago H, Sakai Y et al. (1993). Production and characterization of specific asialoglycoprotein receptor antibodies. Hybridoma, 12:591–598.
   PubMed Web of Science ®Google Scholar
• Fiume L, Di Stefano G, Busi C, Mattioli A, Bonino F, Torrani-Cerenzia M et al. (1997). Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor. J Viral Hepat, 4:363–370.
   PubMed Web of Science ®Google Scholar
• Morille M, Passirani C, Letrou-Bonneval E, Benoit JP, Pitard B. (2009). Galactosylated DNA lipid nanocapsules for efficient hepatocyte targeting. Int J Pharm, 379:293–300.
   PubMed Web of Science ®Google Scholar
• Wang SN, Deng YH, Xu H, Wu HB, Qiu YK, Chen DW. (2006). Synthesis of a novel galactosylated lipid and its application to the hepatocyte-selective targeting of liposomal doxorubicin. Eur J Pharm Biopharm, 62:32–38.
   PubMed Web of Science ®Google Scholar
• Akamatsu K, Yamasaki Y, Nishikawa M, Takakura Y, Hashida M. (1999). Development of a hepatocyte-specific prostaglandin E(1) polymeric prodrug and its potential for preventing carbon tetrachloride-induced fulminant hepatitis in mice. J Pharmacol Exp Ther, 290:1242–1249.
   PubMed Web of Science ®Google Scholar
• Mitchell JP, Roberts KD, Langley J, Koentgen F, Lambert JN. (1999). A direct method for the formation of peptide and carbohydrate dendrimers. Bioorg Med Chem Lett, 9:2785–2788.
   PubMed Web of Science ®Google Scholar
• Tewes F, Munnier E, Antoon B, NgaboniOkassa L, Cohen-Jonathan S, Marchais H et al. (2007). Comparative study of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods. Eur J Pharm Biopharm, 66:488–492.
   PubMed Web of Science ®Google Scholar
• Bahrami G, Mirzaeei Sh, Kiani A. (2005). Determination of acyclovir in human serum by high-performance liquid chromatography using liquid-liquid extraction and its application in pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci, 816:327–331.
   PubMed Web of Science ®Google Scholar
• Nimje N, Agarwal A, Saraogi GK, Lariya N, Rai G, Agrawal H et al. (2009). Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. J Drug Target, 17:777–787.
   PubMed Web of Science ®Google Scholar
• Yadav AK, Agarwal A, Rai G, Mishra P, Jain S, Mishra AK et al. (2010). Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracil. Drug Deliv, 17:561–572.
   PubMed Web of Science ®Google Scholar
• Tu J, Zhong S, Li P. (2004). Studies on acyclovir-dextran conjugate: synthesis and pharmacokinetics. Drug Dev Ind Pharm, 30:959–965.
   PubMed Web of Science ®Google Scholar
• Jain A, Agarwal A, Majumder S, Lariya N, Khaya A, Agrawal H et al. (2010). Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release, 148:359–367.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Gupta U, Asthana A, Jain NK. (2009). Dextran conjugated dendritic nanoconstructs as potential vectors for anti-cancer agent. Biomaterials, 30:3588–3596.
   PubMed Web of Science ®Google Scholar
• Jain SK, Gupta Y, Jain A, Saxena AR, Khare P, Jain A. (2008). Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomedicine, 4:41–48.
   PubMed Web of Science ®Google Scholar